WESTFIELD, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Western New England Bancorp, Inc. (the “Company” or “WNEB”) (NasdaqGS: WNEB), the holding company for Westfield Bank (the “Bank”), announced that on May 30, 2025, the Company completed all repurchases under its existing stock repurchase plan (the “2024 Repurchase Plan”) at an average price per share of $8.79. The 2024 Repurchase Plan authorized the Company to repurchase a total of 1.0 million shares of the Company’s common stock, or approximately 4.6% of t ...

Core Viewpoint - CBL International Limited has announced a share repurchase program, reflecting confidence in its long-term potential and commitment to delivering value to shareholders [1][3]. Financial Performance - For FY2024, CBL reported consolidated revenue of $592.52 million, a 35.9% increase from $435.90 million in 2023, driven by a 38.1% increase in sales volume [3]. Strategic Focus - The company aims to expand its market presence, particularly in biofuels, and enhance its global supply network while driving operational efficiency and sustainable growth [4]. - CBL's strategic initiatives include the expansion of ports, diversification of its client base, and commitment to sustainable practices to position itself for growth as market conditions improve [5]. Company Overview - CBL International Limited, established in 2015, is a marine fuel logistics company based in the Asia Pacific region, providing vessel refueling solutions across over 60 major ports [6].

ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company’s management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL. A webcast of the above presentation may be accessed under "Events ...

ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and only in the U.S. and FDA-approved androgen receptor inhibitor (ARi) for the treatment of patients with hormone-sensitive prostate cancer (mHSPC), in combination with androgen deprivation therapy (ADT), with or without chemotherapy.This third approval is based on positive results from the pivotal Phase III ARANOTE trial and bro ...

VANCOUVER, BC and KIBBUTZ YIFAT, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission (the “BCSC”), Beyond Oil Ltd. (CSE: BOIL; OTCQB: BEOLF; Frankfurt: UH9) (“Beyond Oil” or the “Company”) today issued the following press release providing clarifications related to certain German-language promotional media activities. As part of an awarness campaign focused on German speaking audiences, German-language materials referencing Beyond Oil were publishe ...

Core Insights - HeartCore Enterprises, Inc. has signed a Consulting Agreement with tmsuk Co. Ltd. for its 15th Go IPO consulting service win [1][2] - tmsuk will compensate HeartCore with $500,000 in fees and a warrant to acquire 3% of tmsuk's capital stock, subject to shareholder approval [2] - HeartCore's CEO expressed optimism about the demand for Go IPO services from Japanese growth companies despite market uncertainties [3] Company Overview - HeartCore is a leading enterprise software and data consulting services company headquartered in Tokyo, with additional offices in New York and San Francisco [4] - The company offers Software as a Service (SaaS) solutions and data analytics services to enhance customer experiences for enterprise clients [5] - HeartCore's Go IPOSM consulting services assist Japanese companies in going public in the U.S. [6]

Châtillon, France, June 03, 2025 DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced today the filing of an addendum to the 2024 Universal Registration Document (the “Addendum”) with the French market authority, “Autorité des Marchés Financiers” (“AMF”). This Addendum provides an update to the Board of Dir ...

ORLANDO, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Innventure, Inc. (NASDAQ: INV) (“Innventure”), a technology commercialization platform, today announced its participation at the following investor conferences: June 12, 2025 – Lucas Harper, Chief Investment Officer, and Roland Austrup, Chief Growth Officer, will present at Sidoti’s Virtual Small Cap Conference. The presentation will begin at approximately 3:15 p.m. ET and will be webcast live, which can be accessed via Innventure’s Investor Relations website ...

KUALA LUMPUR, MALAYSIA, June 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has received a letter (the “Compliance Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”) dated June 3, 2025, informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price R ...

Acquisition Advances Permian Basin Growth Strategy TULSA, Okla., June 3, 2025 /PRNewswire/ -- ONEOK, Inc. (NYSE: OKE) today announced the acquisition of the remaining 49.9% interest in Delaware G&P LLC (Delaware Basin JV) from NGP XI Midstream Holdings, L.L.C. for $940 million, consisting of $530 million in cash and $410 million in ONEOK common stock.  Delaware Basin JV owns natural gas gathering and processing facilities in the Delaware Basin in West Texas and New Mexico, with a total processing capacity o ...